Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Glucagon Like Peptide 2 Receptor (GLP2R) – Pipeline Review, H2 2016’, provides in depth analysis on Glucagon Like Peptide 2 Receptor (GLP2R) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)

The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Naia Limited

Shire Plc

Tasly Pharmaceutical Group Co., Ltd.

Zealand Pharma A/S

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Glucagon Like Peptide 2 Receptor (GLP2R) Overview 6

Therapeutics Development 7

Glucagon Like Peptide 2 Receptor (GLP2R) - Products under Development by Stage of Development 7

Glucagon Like Peptide 2 Receptor (GLP2R) - Products under Development by Therapy Area 8

Glucagon Like Peptide 2 Receptor (GLP2R) - Products under Development by Indication 9

Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Glucagon Like Peptide 2 Receptor (GLP2R) - Products under Development by Companies 12

Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development 19

Naia Limited 19

Shire Plc 20

Tasly Pharmaceutical Group Co., Ltd. 21

Zealand Pharma A/S 22

Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles 23

FE-203799 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

glepaglutide - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

GXG-8 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

NB-1002 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

teduglutide - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ZPGG-23 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ZPGG-72 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Projects 35

Glucagon Like Peptide 2 Receptor (GLP2R) - Featured News & Press Releases 36

Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS) 36

May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome 37

Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 38

Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome 38

Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX 39

Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan 39

Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data 40

Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association’s (ADA) 74th Scientific Sessions 41

Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome 41

Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection 42

Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome 43

Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting 44

Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome 45

Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults 47

Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 18

Pipeline by Naia Limited, H2 2016 19

Pipeline by Shire Plc, H2 2016 20

Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 21

Pipeline by Zealand Pharma A/S, H2 2016 22

Dormant Projects, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports